| scholarly article | Q13442814 |
| P50 | author | Eleanor Wilson | Q40899810 |
| P2093 | author name string | L Tang | |
| H Ward | |||
| S Kottilil | |||
| S Kattakuzhy | |||
| P2860 | cites work | The association between hepatitis C infection and survival after orthotopic liver transplantation | Q42672810 |
| Hepatitis C virus kinetics during and immediately after liver transplantation. | Q43036834 | ||
| Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation | Q45740469 | ||
| The metabolism of ribavirin in erythrocytes and nucleated cells | Q46071227 | ||
| Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. | Q50569800 | ||
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
| EASL Recommendations on Treatment of Hepatitis C 2015 | Q58324800 | ||
| Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 | ||
| Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
| A 2015 roadmap for the management of hepatitis C virus infections in Asia | Q28088762 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 | ||
| Mechanism of action of ribavirin in the combination treatment of chronic HCV infection | Q34618481 | ||
| Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial | Q34624732 | ||
| Global burden of disease (GBD) for hepatitis C. | Q35610002 | ||
| Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response | Q35933802 | ||
| Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin | Q35975174 | ||
| Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. | Q36446122 | ||
| Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection | Q37202576 | ||
| Sofosbuvir for treatment of chronic hepatitis C. | Q38383410 | ||
| Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. | Q38976884 | ||
| Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus | Q39376758 | ||
| Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry | Q39412692 | ||
| Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients | Q39913723 | ||
| Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression | Q39935106 | ||
| Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. | Q40795101 | ||
| Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. | Q40936553 | ||
| Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. | Q41066364 | ||
| Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens | Q41196998 | ||
| Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study | Q41497390 | ||
| Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation | Q41564280 | ||
| Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation | Q41705891 | ||
| Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. | Q41722679 | ||
| Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study | Q41724402 | ||
| Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial | Q41750256 | ||
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3. | Q42220605 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| sofosbuvir | Q2502747 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 21-36 | |
| P577 | publication date | 2015-12-11 | |
| P1433 | published in | Expert Review of Gastroenterology & Hepatology | Q15733730 |
| P1476 | title | Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection | |
| P478 | volume | 10 |
Search more.